High-strength testosterone undecanoate compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C max to serum testosterone C ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C ave range for a male subject is provided.
1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
(a) Orally administering to said male a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier, that provides from about 360 mg to about 480 mg of testosterone undecanoate to said male per day;
(b) Determining the serum level of testosterone of said male during the daily dosing regimen at from 1-8 hours after a single dose administration of said pharmaceutical composition at steady state; and
(c) Orally administering a maintenance daily dosing regimen of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 360 mg to about 480 mg of testosterone undecanoate to said male based on the serum testosterone level determined in step (b),
to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL,
wherein said carrier comprises a fatty acid and a polyoxyethylene hydrogenated vegetable oil.
2. The method of claim 1 , wherein said carrier further comprises a triglyceride.
3. The method of claim 1 , wherein said carrier further comprises a monoglyceride, diglyceride or both.
4. The method of claim 1 , wherein said carrier comprises a fatty acid which is oleic acid.
5. The method of claim 1 , wherein said carrier comprises a polyoxyethylene hydrogenated vegetable oil which is Cremophor RH 40.
6. The method of claim 1 , wherein said carrier further comprises tocopherol.
7. The method of claim 1 , wherein said daily dosing regimen or maintenance daily dosing regimen comprises twice daily dosing with said pharmaceutical composition.
8. The method of claim 1 , wherein said orally administering comprises administration of the pharmaceutical composition with a meal.
9. The method of claim 1 , wherein said carrier further comprises an antioxidant.
10. The method of claim 1 , wherein said pharmaceutical composition has at least 5% of said testosterone undecanoate not dissolved and at least 33% dissolved in said carrier.
11. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
(a) Orally administering to said male a daily dosing regimen of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier to provide from about 350 mg testosterone undecanoate to about 650 mg testosterone undecanoate to said male per day;
(b) determining the serum level of testosterone of said male during the daily dosing regimen at a single time point from 1-8 hours after single dose administration of said pharmaceutical composition at steady state, C t ; and
(c) orally administering a maintenance daily dosing regimen of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 350 mg to about 650 mg of testosterone undecanoate to said male based on the serum testosterone level determined in step (b),
said carrier comprising a fatty acid and a polyoxyethylene hydrogenated vegetable oil, to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
12. The method of claim 11 , wherein said carrier further comprises a triglyceride.
13. The method of claim 11 , wherein said carrier further comprises a monoglyceride, diglyceride or both.
14. The method of claim 11 , wherein said carrier comprises a fatty acid which is oleic acid.
15. The method of claim 11 , wherein said carrier comprises a polyoxyethylene hydrogenated vegetable oil which is Cremophor RH 40.
16. The method of claim 11 , wherein said carrier further comprises an antioxidant.
17. The method of claim 11 , wherein said daily dosing regimen or maintenance daily dosing regimen comprises twice daily dosing with said pharmaceutical composition.
18. The method of claim 11 , wherein said orally administering comprises administration of the pharmaceutical composition with a meal.
19. The method of claim 11 , wherein said pharmaceutical composition has at least 5% of said testosterone undecanoate not dissolved and at least 33% dissolved.
20. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone, said method comprising:
(a) Orally administering to said male a daily dosing regimen of a pharmaceutical composition comprising about 14% to about 35% testosterone undecanoate and a carrier to provide from about 360 mg testosterone undecanoate to about 480 mg testosterone undecanoate to said male per day;
(b) determining the serum level of testosterone of said male during the daily dosing regimen at a single time point from 1-8 hours after single dose administration of said pharmaceutical composition at steady state, C t ; and
(c) orally administering a maintenance daily dosing regimen of a pharmaceutical composition comprising about 14% to about 35% testosterone undecanoate and a carrier, that provides within plus or minus 40% of from about 360 mg to about 480 mg of testosterone undecanoate to said male subject based on the serum testosterone level determined in step (b),
said carrier comprising oleic acid and Cremophor RH 40,
to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
21. The method of claim 20 , wherein said carrier further comprises a monoglyceride, a diglyceride, a triglyceride, an antioxidant or a combination thereof.
22. The method of claim 1 , when used with a group of males provides a mean C ave serum testosterone concentration in the range of about 350 ng/dL to 800 ng/dL.
23. The method of claim 11 , when used with a group of males provides a mean C ave serum testosterone concentration in the range of about 350 ng/dL to 800 ng/dL.
24. The method of claim 20 , when used with a group of males provides a mean C ave serum testosterone concentration in the range of about 350 ng/dL to 800 ng/dL.